文献速递膀胱癌与上尿路尿路上皮癌

Bladder EpiCheck™甲基化检测在非肌层浸润性膀胱癌监测患者中的性能:多中心前瞻性盲法临床试验结果

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
PubMed 文献 · Eur Urol Oncol · 2018-07-17

这项盲法、单臂、前瞻性多中心研究纳入440例受监测的非肌层浸润性膀胱癌患者,353例可评估。Bladder EpiCheck检测总体敏感性68.2%、特异性88.0%、阴性预测值95.1%;排除低级别Ta复发后敏感性91.7%、阴性预测值99.3%。作者认为该检测可融入随访,减少重复膀胱镜和细胞学检查负担。

要点

  • Bladder EpiCheck总体阴性预测值95.1%,排除低级别Ta复发后达99.3%。
  • 总体特异性88.0%,可高置信度即时发现高级别复发。
  • 作者认为该检测可融入NMIBC随访,减少重复膀胱镜和细胞学检查负担。

核心结论

  • 在非肌层浸润性膀胱癌患者随访中,Bladder EpiCheck检测总体阴性预测值高,为95.1%,排除低级别Ta复发后为99.3%。
  • 该检测特异性为88.0%,作者认为可融入非肌层浸润性膀胱癌随访,因为高级别复发可被高置信度即时发现,从而可能减少重复膀胱镜和细胞学检查的负担。

研究设计与样本

  • 盲法、单臂、前瞻性多中心研究。
  • 纳入标准为年龄≥22岁、每3个月接受膀胱镜监测的尿路上皮癌患者、所有尿路上皮癌在12个月内切除、能提供10ml尿液、能签署知情同意。
  • 共招募440例患者,其中353例符合性能分析条件。
  • 计算Bladder EpiCheck检测特征,并与细胞学及经病理证实的膀胱镜结果比较。

主要发现

  • 总体敏感性为68.2%,特异性为88.0%,阴性预测值为95.1%,阳性预测值为44.8%。
  • 排除低级别Ta复发后,敏感性为91.7%,阴性预测值为99.3%。
  • 包含和不包含低级别Ta病变的受试者工作特征曲线下面积分别为0.82和0.94。

临床怎么用

  • 作者认为,鉴于特异性为88.0%且高级别复发可被高置信度即时发现,该检测可融入非肌层浸润性膀胱癌随访。
  • 作者认为,在临床常规中使用该检测可减少随访膀胱镜数量,从而减轻患者和经济负担。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The highly frequent strategy of surveillance for non-muscle-invasive bladder cancer (NMIBC) involves cystoscopy and cytology. Urine assays currently available have not shown performance sufficient to replace the current gold standard for follow-up, which would require a very high negative predictive value (NPV), especially for high-grade tumors. Bladder EpiCheck (BE) is a novel urine assay that uses 15 proprietary DNA methylation biomarkers to assess the presence of bladder cancer. OBJECTIVE: To assess the performance of BE for NMIBC recurrence. DESIGN, SETTING, AND PARTICIPANTS: This was a blinded, single-arm, prospective multicenter study. The inclusion criteria were age ≥22 yr, urothelial carcinoma (UC) being monitored cystoscopically at 3-mo intervals, all UC resected within 12 mo, able to produce 10ml of urine, and able to consent. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The BE test characteristics were calculated and compared to cytology and cystoscopy results confirmed by pathology. RESULTS AND LIMITATIONS: Out of 440 patients recruited, 353 were eligible for the performance analysis. Overall sensitivity, specificity, NPV, and positive predictive value were 68.2%, 88.0%, 95.1%, and 44.8%, respectively. Excluding low-grade (LG) Ta recurrences, the sensitivity was 91.7% and NPV was 99.3%. The area under receiver operating characteristic (ROC) curves with and without LG Ta lesions was 0.82 and 0.94, respectively. CONCLUSIONS: In follow-up of NMIBC patients, the BE test showed an overall high NPV of 95.1%, and 99.3% when excluding LG Ta recurrences. With high specificity of 88.0%, the test could be incorporated in NMIBC follow-up since high-grade recurrences would be instantly detected with high confidence. Thus, the current burden of repeat cystoscopies and cytology tests could be reduced. PATIENT SUMMARY: The Bladder EpiCheck urine test has a clinically relevant and high negative predictive value. Its use in clinical routine could reduce the number of follow-up cystoscopies, and thus associated patient and financial burdens.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Witjes JA, Morote J, Cornel EB, et al. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. Eur Urol Oncol. 2018. PMID: 31100252. doi:10.1016/j.euo.2018.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。